Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …

Targeted radionuclide therapy is one of the most intensively developing directions of nuclear
medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy …

The remarkable clinical success of immune-checkpoint inhibitors for the treatment of a
growing number of cancer types has sparked interest in the discovery of novel forms of …

Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which
typically do not preferentially localize at the tumor site and cause toxicity to normal organs …

Bioorthogonal click chemistry—employing antibody-conjugated trans-cyclooctenes (TCO)
and tetrazine (Tz)-based radioligands able to covalently bind in vivo—appeared recently as …

Cytokines have long been used for therapeutic applications in cancer patients. Substantial
side effects and unfavorable pharmacokinetics limit their application and may prevent dose …

It is generally thought that the anticancer efficacy of antibody–drug conjugates (ADC) relies
on their internalization by cancer cells. However, recent work on an ADC that targets …

Cytokine-based therapeutics have been shown to mediate objective responses in certain
tumor entities but suffer from insufficient selectivity, causing limiting toxicity which prevents …

Monoclonal antibodies (mAbs) and their derivatives have emerged as one of the most
important classes of biotherapeutics in recent decades. The success of mAb is due to their …

The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy
adults and is almost exclusively expressed by newly formed blood vessels in tumours …